ReCor Medical today announced it appointed Lara Barghout as president and CEO. Barghout will succeed Andrew Weiss. She will lead the Palo Alto, California-based company’s business strategy and organization in a new direction, according to the company. The goal is to commercialize ReCor’s Paradise ultrasound renal denervation (uRDN) system that treats hypertension. “I am honored […]
renal denervation
ReCor reports more positive ultrasound renal denervation results
ReCor Medical said its Paradise ultrasound renal denervation (uRDN) treatment showed consistent and significant blood pressure reductions in an analysis of pooled data from ReCor’s three Radiance randomized hypertension studies. “Pooling the data from the Radiance program demonstrates that treatment with the Paradise uRDN System results in a consistent reduction in blood pressure across differing […]
Medtronic RDN trial fails to beat hypertension drugs; data submitted for FDA review
Medtronic (NYSE:MDT) said its Symplicity Spyral renal denervation (RDN) system for treating hypertension failed to outperform blood pressure drugs in the latest trial results. However, the SPYRAL HTN-ON MED clinical trial’s six-month results did show improvement over Medtronic’s previous RDN efforts, the device maker said in a news release. RDN is designed to treat hypertension […]
4 major cardiology trends you need to know from TCT 2022
Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive. The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations. Medtronic, Abbott, Edwards and Boston Scientific represent a few of the […]
ReCor Medical ultrasound renal denervation trial meets primary efficacy endpoint
ReCor Medical announced that a trial for its Paradise ultrasound renal denervation (uRDN) treatment met its primary efficacy endpoint. Palo Alto, California-based ReCor’s RADIANCE II pivotal trial evaluated Paradise as a treatment for hypertension. The trial operated under FDA investigational device exemption. ReCor presented results at TCT 2022 in Boston. They follow the company’s July […]
Study shows blood pressure reduction with Medtronic renal denervation procedure
Medtronic (NYSE:MDT) announced study data that it says demonstrates significant blood pressure reduction with the Symplicity renal denervation system. The SYMPLICITY HTN-3 clinical trial observed subjects who underwent radiofrequency renal denervation (RF RDN) with first-generation Symplicity. Results demonstrated a statistically significant reduction in office and ambulatory blood pressure compared to a sham control group. Medtronic’s […]
Medtronic’s renal denervation system demonstrates better blood pressure control, time in range
Medtronic (NYSE:MDT) announced today that new data supports the use of its Symplicity Spyral renal denervation (RDN) system. As part of the medtech giant’s Spyral HTN global clinical program, three-year data from the Spyral HTN-ON MED and GSR-Define trials were presented at EuroPCR 2022 as late-breaking clinical trials demonstrating the benefit of the Symplicity blood […]
Medtronic releases new renal denervation results, closes trial enrollment
Medtronic (NYSE:MDT) today said its Symplicity Spyral renal denervation (RDN) system demonstrated durable, clinically significant blood pressure reductions through three years for patients on medication. It’s the latest development out of Medtronic’s Spyral HTN-ON MED trial testing the company’s RDN catheter system, which delivers radiofrequency energy to overactive nerves near the kidneys that cause high blood pressure. […]
Some analysts are upbeat about Medtronic’s renal denervation prospects
Needham & Co. analysts are reiterating their Buy rating for Medtronic stock, saying that renal denervation (RDN) could still be a big opportunity for the medtech giant. Medtronic (NYSE:MDT) had to continue its Spyral HTN-ON MED trial into this year after failing to obtain the positive results needed to end enrollment early for the potential […]
MedtronicTalks: Why Symplicity Spyral trials are complicated, but worth it
Medtronic’s campaign to secure FDA approval of its renal denervation device — Symplicity Spyral — has been anything but simple. But in this episode of the MedtronicTalks podcast, Jason Weidman, SVP and president of Coronary & Renal Denervation, explains why the company has refused to give up the fight to develop the renal denervation tool […]
Medtronic builds suspense for renal denervation study results
Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference. The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar […]
